Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS: Fremanezumab for migraine prophylaxis
NCT03308968Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of fremanezumab in migraine, sponsored by Teva Pharmaceutical Industries Ltd.. Started Oct 2017; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03308968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308968.